Literature DB >> 19173754

Should noninvasive ventilation be used with the do-not-intubate patient?

Robert M Kacmarek1.   

Abstract

Most of the large quantity of data on noninvasive ventilation (NIV) in acute respiratory failure is from patients who want all possible treatments and life-support. Few data are available on NIV in patients who have elected specific limits on life support and treatments (eg, patients with do-not-intubate [DNI] orders) and patients who are near the end of life and will receive comfort measures only (CMO). The most critical issue regarding NIV in DNI and CMO patients is informed consent. The patient must be informed of the risks and potential benefits of NIV, and must consent to NIV. We have few data on patients' attitudes about NIV at end of life. Data from cancer patients at end of life suggest that they want to maintain control over care decisions and may want treatment that delays death long enough that they can put their affairs in order. If informed consent and control of care decisions are assured, then NIV can be appropriate in DNI and CMO patients to reverse an acute respiratory failure that is not necessarily life-terminating, or to improve patient comfort, or to delay death.

Entities:  

Mesh:

Year:  2009        PMID: 19173754

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  2 in total

1.  Results of noninvasive ventilation in very old patients.

Authors:  Frederique Schortgen; Arnaud Follin; Lucilla Piccari; Ferran Roche-Campo; Guillaume Carteaux; Elodie Taillandier-Heriche; Sebastien Krypciak; Arnaud W Thille; Elena Paillaud; Laurent Brochard
Journal:  Ann Intensive Care       Date:  2012-02-21       Impact factor: 6.925

2.  Comparison of high-flow nasal oxygen therapy and non-invasive ventilation in ICU patients with acute respiratory failure and a do-not-intubate orders: a multicentre prospective study OXYPAL.

Authors:  René Robert; Denis Frasca; Julie Badin; C Girault; Christophe Guitton; Michel Djibre; Pascal Beuret; Jean Reignier; Dalila Benzekri-Llefevre; Suela Demiri; Hassène Rahmani; Laurent Argaud Argaud; Erwan I'her; Stephan Ehrmann; Olivier Lesieur; Khaldoune Kuteifan; Francois Thouy; Laura Federici; Didier Thevenin; Damien Contou; Nicolas Terzi; Saad Nseir; Martial Thyrault; Christophe Vinsonneau; Juliette Audibert; Juliette Masse; Alexandre Boyer; Bertrand Guidet; Riad Chelha; Jean-Pierre Quenot; G Piton; Nadia Aissaoui; Arnaud W Thille; Jean-Pierre Frat
Journal:  BMJ Open       Date:  2021-02-12       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.